Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Royan Stem Cell Technology Company

Clinicaltrial registered3 Nov 2026

Royan Stem Cell Technology Company

3 Nov 2026: Trial registered · ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic Stroke. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
3 Nov 2026
Title
ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Iran
Country
Iran
Reference
NCT07913282
Location
Iran
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Royan Stem Cell Technology Company

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Iran

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.